Director dealings: Roquefort Therapeutics director raises stake
By Iain Gilbert
Date: Monday 24 Nov 2025
(Sharecast News) - Roquefort Therapeutics revealed on Monday that interim managing director Darrin Disley had acquired 5.0m ordinary shares in the London-listed material biotech company.
Disley, who joined Roquefort in September 2022, purchased the shares on Friday at an average price of 1.70p each, for a total value of £85,000.
As a result of the transaction, Disley now holds a beneficial interest in 7.02m ordinary Roquefort shares, representing approximately 4.46% of Roquefort's issued share capital.
As of 1530 GMT, Roquefort shares were up 1.29% at 1.92p.
Reporting by Iain Gilbert at Sharecast.com
Top Director Buys
Roquefort Therapeutics (ROQ)
Director name: Disley,Dr Darrin
Amount purchased: 5,000,000 @ 170.00p
Value: £85,000
Mobius Investment Trust (MMIT)
Director name: Dyer Bartlett ,Diana
Amount purchased: 21,469 @ 137.50p
Value: £29,519.88
Grainger (GRI)
Director name: Fraser,Simon
Amount purchased: 15,000 @ 183.00p
Value: £27,450.00
Paypoint (PAY)
Director name: Harding,Rob
Amount purchased: 1,924 @ 519.00p
Value: £9,985.56
Top Director Sells
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN